65,437 trials
Cervical Squamous Cell Carcinoma · Recurrent Cervical Cancer
Primary: Progression-free Survival Greater Than 6 Months — 23.9 percentage of participants
Alcohol Consumption
Primary: Drinks Per Week — 12.55; 9.57; 13.74 drinks per week
Choledocholithiasis · Cholangiocarcinoma · Pancreatitis
Primary: Number of Intervention — 1.9; 7.5 Number of intervention — p=0.05
End Stage Renal Disease
Primary: The Percent of Sensitized Patients Treated With PRA Reduction Pharmacological Therapy, Including Cytogam, Who Become Cross-match Compatible With Potential Living Donor…
Borderline Ovarian Serous Tumor · Low Grade Ovarian Serous Adenocarcinoma · Micropapillary Serous Carcinoma
Primary: Tumor Response — 15.4 percentage of patients
Body Dysmorphic Disorder
Primary: Change in Total Score on the BDD-Y-BOCS Scale — -12.27; -9.53 units on a scale
Leukemia, Lymphocytic, Acute
Primary: Complete Response (CR) Rate — 28 percentage of participants
Chronic Heart Failure
Primary: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. — 793; 937…
Surgery
Primary: Occurence of Adverse Cardiac Events — 91 participants
Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Tolerated Dose — 80 mg/m^2
Clinical Pharmacology
Primary: AUC (0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Postdose for Unchanged SYR-322 (SYR-322Z) — 1494.9; 1472.8 nanogram*milliliter per…
Depression · Substance Abuse · Substance Use
Primary: HAMD Rating Scores — 16.86; 10.71; 9.81; 7.33 Units on a scale
Solid Cancers
Primary: Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Rosiglitazone — 92.0 ng/mL*hr
Myopia
Primary: Percentage of Eyes With Loss of More Than 2 Lines Best Spectacle Corrected Visual Acuity (BSCVA) — 0 percentage of eyes
Malignant Glioma
Primary: Effects of Low-dose Naltrexone Versus Placebo on Change in Quality of Life (QoL) in High-grade Glioma Patients Undergoing Standard Chemoradiation From Baseline — -3.73…